Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26543786,flow rate,"After protein precipitation extraction, the chromatography separation of analyte and internal standard named eltrombopag as an marketed analog of hetrombopag was performed on an Synergi Polar-RP column at the flow rate of 0.5 mL/min, and the determination was conducted on an API4000 triple quadrupole mass spectrometry in the multiple reaction monitoring mode using the respective [M+H](+) ions m/z 459.2 → 200.9 for hetrombopag and m/z 443.2 → 229.0 for IS.",Development and validation of a LC-MS/MS method for quantification of hetrombopag for pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26543786/),[ml] / [min],0.5,23675,DB06210,Eltrombopag
,25929594,PLTC,"Simulations showed that ~70% to 80% of steady-state PLTC response was achieved at week 2, and the percentages of patients who achieved a PLTC of 50 to 150 × 10(9) cells/L were comparable between weeks 2 and 6 with 12.5-, 25-, 50-, and 75-mg once-daily dosing.",Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25929594/),,50,32362,DB06210,Eltrombopag
>,25929594,PLTC,"No more than 5% of patients who underwent dose titration had a PLTC >250 × 10(9) cells/L throughout 24 weeks of treatment, compared with 3%, 7%, 16%, and 24% when the once-daily fixed doses of eltrombopag were given.",Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25929594/),[cells] / [l],250,32363,DB06210,Eltrombopag
,22409309,response rate,"The response rate (platelet count of ≥ 50,000 μL(-1) ) at week 6 of the 6-week double-blind phase was 60% in eltrombopag-treated patients and 0% in placebo-treated patients.",A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22409309/),%,60,76065,DB06210,Eltrombopag
,22409309,response rate,"The response rate (platelet count of ≥ 50,000 μL(-1) ) at week 6 of the 6-week double-blind phase was 60% in eltrombopag-treated patients and 0% in placebo-treated patients.",A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22409309/),%,0,76066,DB06210,Eltrombopag
,30171280,t1/2,"The geometric mean t1/2 was ≈ 21, ≈ 24, and ≈ 26 h, respectively, in cyclosporine 200 mg + eltrombopag, cyclosporine 600 mg + eltrombopag and eltrombopag alone groups.",Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30171280/),h,21,133454,DB06210,Eltrombopag
,30171280,t1/2,"The geometric mean t1/2 was ≈ 21, ≈ 24, and ≈ 26 h, respectively, in cyclosporine 200 mg + eltrombopag, cyclosporine 600 mg + eltrombopag and eltrombopag alone groups.",Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30171280/),h,24,133455,DB06210,Eltrombopag
,30171280,t1/2,"The geometric mean t1/2 was ≈ 21, ≈ 24, and ≈ 26 h, respectively, in cyclosporine 200 mg + eltrombopag, cyclosporine 600 mg + eltrombopag and eltrombopag alone groups.",Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30171280/),h,26,133456,DB06210,Eltrombopag
,29949502,clearance,"Ceftriaxone pharmacokinetics in healthy adults were described using a bicompartmental model, with a mean clearance of 0.96 L/h (CI95% 0.71-1.20) and AUC0-∞of 1106 mg.h/mL (CI95% 811-1400) for volunteers that received only ceftriaxone; clearance of 0.95 L/h (CI95% 0.77-1.13) and AUC0-∞ of 1083 mg.h/mL (CI95% 876-1290) for volunteers that received ceftriaxone plus 25 mg of eltrombopag and clearance of 0.96 L/h (CI95% 0.74-1.19) and AUC0-∞ of 1072 mg.h/mL (CI95% 872-1273) for volunteers that received ceftriaxone plus 50 mg of eltrombopag.",Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29949502/),[l] / [h],0.96,142205,DB06210,Eltrombopag
,29949502,AUC0-∞,"Ceftriaxone pharmacokinetics in healthy adults were described using a bicompartmental model, with a mean clearance of 0.96 L/h (CI95% 0.71-1.20) and AUC0-∞of 1106 mg.h/mL (CI95% 811-1400) for volunteers that received only ceftriaxone; clearance of 0.95 L/h (CI95% 0.77-1.13) and AUC0-∞ of 1083 mg.h/mL (CI95% 876-1290) for volunteers that received ceftriaxone plus 25 mg of eltrombopag and clearance of 0.96 L/h (CI95% 0.74-1.19) and AUC0-∞ of 1072 mg.h/mL (CI95% 872-1273) for volunteers that received ceftriaxone plus 50 mg of eltrombopag.",Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29949502/),[h·mg] / [ml],1106,142206,DB06210,Eltrombopag
,29949502,clearance,"Ceftriaxone pharmacokinetics in healthy adults were described using a bicompartmental model, with a mean clearance of 0.96 L/h (CI95% 0.71-1.20) and AUC0-∞of 1106 mg.h/mL (CI95% 811-1400) for volunteers that received only ceftriaxone; clearance of 0.95 L/h (CI95% 0.77-1.13) and AUC0-∞ of 1083 mg.h/mL (CI95% 876-1290) for volunteers that received ceftriaxone plus 25 mg of eltrombopag and clearance of 0.96 L/h (CI95% 0.74-1.19) and AUC0-∞ of 1072 mg.h/mL (CI95% 872-1273) for volunteers that received ceftriaxone plus 50 mg of eltrombopag.",Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29949502/),[l] / [h],0.95,142207,DB06210,Eltrombopag
,29949502,AUC0-∞,"Ceftriaxone pharmacokinetics in healthy adults were described using a bicompartmental model, with a mean clearance of 0.96 L/h (CI95% 0.71-1.20) and AUC0-∞of 1106 mg.h/mL (CI95% 811-1400) for volunteers that received only ceftriaxone; clearance of 0.95 L/h (CI95% 0.77-1.13) and AUC0-∞ of 1083 mg.h/mL (CI95% 876-1290) for volunteers that received ceftriaxone plus 25 mg of eltrombopag and clearance of 0.96 L/h (CI95% 0.74-1.19) and AUC0-∞ of 1072 mg.h/mL (CI95% 872-1273) for volunteers that received ceftriaxone plus 50 mg of eltrombopag.",Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29949502/),[h·mg] / [ml],1083,142208,DB06210,Eltrombopag
,29949502,clearance,"Ceftriaxone pharmacokinetics in healthy adults were described using a bicompartmental model, with a mean clearance of 0.96 L/h (CI95% 0.71-1.20) and AUC0-∞of 1106 mg.h/mL (CI95% 811-1400) for volunteers that received only ceftriaxone; clearance of 0.95 L/h (CI95% 0.77-1.13) and AUC0-∞ of 1083 mg.h/mL (CI95% 876-1290) for volunteers that received ceftriaxone plus 25 mg of eltrombopag and clearance of 0.96 L/h (CI95% 0.74-1.19) and AUC0-∞ of 1072 mg.h/mL (CI95% 872-1273) for volunteers that received ceftriaxone plus 50 mg of eltrombopag.",Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29949502/),[l] / [h],0.96,142209,DB06210,Eltrombopag
,29949502,AUC0-∞,"Ceftriaxone pharmacokinetics in healthy adults were described using a bicompartmental model, with a mean clearance of 0.96 L/h (CI95% 0.71-1.20) and AUC0-∞of 1106 mg.h/mL (CI95% 811-1400) for volunteers that received only ceftriaxone; clearance of 0.95 L/h (CI95% 0.77-1.13) and AUC0-∞ of 1083 mg.h/mL (CI95% 876-1290) for volunteers that received ceftriaxone plus 25 mg of eltrombopag and clearance of 0.96 L/h (CI95% 0.74-1.19) and AUC0-∞ of 1072 mg.h/mL (CI95% 872-1273) for volunteers that received ceftriaxone plus 50 mg of eltrombopag.",Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29949502/),[h·mg] / [ml],1072,142210,DB06210,Eltrombopag
,22674141,maximum plasma concentration (C(max)),"Pharmacokinetics showed that the geometric means of the maximum plasma concentration (C(max)) and the area under the curve (AUC) in the 12.5 mg group were 3,413 ng/mL and 65,236 ng h/mL, respectively.","Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674141/),[ng] / [ml],"3,413",152029,DB06210,Eltrombopag
,22674141,area under the curve (AUC),"Pharmacokinetics showed that the geometric means of the maximum plasma concentration (C(max)) and the area under the curve (AUC) in the 12.5 mg group were 3,413 ng/mL and 65,236 ng h/mL, respectively.","Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674141/),[h·ng] / [ml],"65,236",152030,DB06210,Eltrombopag
,24887483,flow rate,"The chromatographic separation was achieved on a C18 column by using a mixture of 10mM ammonium formate (pH3) and acetonitrile (10:90, v/v) as the mobile phase at a flow rate of 1.0mL/min.",Liquid chromatography-tandem mass spectrometric assay for eltrombopag in 50μL of human plasma: a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24887483/),[ml] / [min],1.0,188328,DB06210,Eltrombopag
,29948848,distributional clearance,"Typical value for distributional clearance was 0.762 L/h (95% Bayesian credible set, 0.703-0.826), for volume of distribution of the central and peripheral compartments were 12 L (10.9-13.4) and 10.9 L (10.4-11.5), and for absorption lag time was 0.947 h (0.918-0.977).",Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948848/),[l] / [h],0.762,232099,DB06210,Eltrombopag
,29948848,volume of distribution of the central,"Typical value for distributional clearance was 0.762 L/h (95% Bayesian credible set, 0.703-0.826), for volume of distribution of the central and peripheral compartments were 12 L (10.9-13.4) and 10.9 L (10.4-11.5), and for absorption lag time was 0.947 h (0.918-0.977).",Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948848/),l,12,232100,DB06210,Eltrombopag
,29948848,volume of distribution of the central,"Typical value for distributional clearance was 0.762 L/h (95% Bayesian credible set, 0.703-0.826), for volume of distribution of the central and peripheral compartments were 12 L (10.9-13.4) and 10.9 L (10.4-11.5), and for absorption lag time was 0.947 h (0.918-0.977).",Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948848/),l,10.9,232101,DB06210,Eltrombopag
,29948848,absorption lag time,"Typical value for distributional clearance was 0.762 L/h (95% Bayesian credible set, 0.703-0.826), for volume of distribution of the central and peripheral compartments were 12 L (10.9-13.4) and 10.9 L (10.4-11.5), and for absorption lag time was 0.947 h (0.918-0.977).",Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948848/),h,0.947,232102,DB06210,Eltrombopag
,29948848,elimination clearance,"Assuming an average total bilirubin of 21.7 µmol/L, the typical elimination clearance value for an East Asian patient was 0.14 L/h and for other races was 0.20 L/h.",Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948848/),[l] / [h],0.14,232103,DB06210,Eltrombopag
,29948848,elimination clearance,"Assuming an average total bilirubin of 21.7 µmol/L, the typical elimination clearance value for an East Asian patient was 0.14 L/h and for other races was 0.20 L/h.",Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948848/),[l] / [h],0.20,232104,DB06210,Eltrombopag
,20663993,apparent clearance (CL/F),"For a typical 70-kg Caucasian male ITP patient not taking corticosteroids, estimated parameters were apparent clearance (CL/F) = 0.668 L/h, apparent volume of the central compartment (Vc/F) = 8.76 L, apparent volume of the peripheral compartment (Vp/F) = 11.3 L, and distributional clearance (Q/F) = 0.399 L/h.",Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663993/),[l] / [h],0.668,268085,DB06210,Eltrombopag
,20663993,apparent volume of the central compartment (Vc/F),"For a typical 70-kg Caucasian male ITP patient not taking corticosteroids, estimated parameters were apparent clearance (CL/F) = 0.668 L/h, apparent volume of the central compartment (Vc/F) = 8.76 L, apparent volume of the peripheral compartment (Vp/F) = 11.3 L, and distributional clearance (Q/F) = 0.399 L/h.",Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663993/),l,8.76,268086,DB06210,Eltrombopag
,20663993,apparent volume of the peripheral compartment (Vp/F),"For a typical 70-kg Caucasian male ITP patient not taking corticosteroids, estimated parameters were apparent clearance (CL/F) = 0.668 L/h, apparent volume of the central compartment (Vc/F) = 8.76 L, apparent volume of the peripheral compartment (Vp/F) = 11.3 L, and distributional clearance (Q/F) = 0.399 L/h.",Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663993/),l,11.3,268087,DB06210,Eltrombopag
,20663993,distributional clearance (Q/F),"For a typical 70-kg Caucasian male ITP patient not taking corticosteroids, estimated parameters were apparent clearance (CL/F) = 0.668 L/h, apparent volume of the central compartment (Vc/F) = 8.76 L, apparent volume of the peripheral compartment (Vp/F) = 11.3 L, and distributional clearance (Q/F) = 0.399 L/h.",Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663993/),[l] / [h],0.399,268088,DB06210,Eltrombopag
